Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardio-Renal and Oncology Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RENALASE drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RENALASE Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native fold. |
View RENALASE Products |
| Gene Delivery | RENALASE Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View RENALASE Products |
| Benchmark Ab | Anti-RENALASE Recombinant Antibody Recombinant positive control matching peer-reviewed functional clones. |
View RENALASE Products |
| Validator | RENALASE siRNA Set Target-specific knockdown verification in tumor and renal cell lines. |
View RENALASE Products |
| Related Target A | ATP2B4 (PMCA4) The primary functional cell-membrane receptor for extracellular Renalase signaling. |
View ATP2B4 Products |
| Related Target B | AKT1 Downstream survival pathway node activated by the Renalase-PMCA4 interaction. |
View AKT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing enzymatic vs. cytokine signaling pathways | Sequence-verified wild-type and structural domain-focused recombinant proteins. |
| Multi-pass membrane receptor (PMCA4) conformation | Lentivirus premade particles optimized for robust stable cell line generation. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live RENALASE/RNLS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development of Renalase (RNLS) represents a unique dual-front paradigm in modern medicine. Originally discovered as a kidney-secreted flavin adenine dinucleotide (FAD)-dependent amine oxidase, Renalase is now recognized as a powerful survival cytokine. This dual nature split the clinical pipeline into two distinct directions: agonist therapies (recombinant Renalase) aimed at treating acute kidney injury (AKI), chronic kidney disease (CKD), and ischemic cardiac events, and antagonist therapies (monoclonal antibodies and small molecules) designed to disrupt the Renalase-PMCA4 signaling axis in oncology.
The race for RENALASE therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeted peptide inhibitors and combination immunotherapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific disruption of the cytokine binding site on PMCA4 while sparing the enzymatic pocket, minimizing systemic cardiovascular side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | Personal Rx, Yale University | Pancreatic Cancer, Melanoma, Solid Tumors | Receptor binding inhibition assay (Need high-purity RENALASE and PMCA4-expressing target cells) |
| Recombinant Protein (Agonist) | Academic Medical Centers, BioPharma | Acute Kidney Injury (AKI), Myocardial Infarction | Enzymatic activity assays & pharmacokinetic profiling (Need sequence-verified, endotoxin-controlled protein) |
| Peptide Inhibitors | Biotech Startups | Inflammatory Diseases, Oncology | Competitive binding assays (Need stable, native-glycosylated target proteins) |